Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Jul 15. pii: jrheum.141128. [Epub ahead of print]

PMID:
26178279
2.

Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases.

Martín S, Del Agua AR, Torres N, Pascual-Salcedo D, Plasencia C, Ruiz-Argüello B, Martínez A, Navarro R, Nagore D.

Clin Chem Lab Med. 2015 May 6. pii: /j/cclm.ahead-of-print/cclm-2015-0266/cclm-2015-0266.xml. doi: 10.1515/cclm-2015-0266. [Epub ahead of print] No abstract available.

PMID:
25945722
3.

Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.

Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Marquez A, Martin J, Gómez-Reino JJ, Gonzalez A.

Pharmacogenomics J. 2015 Apr 21. doi: 10.1038/tpj.2015.29. [Epub ahead of print]

PMID:
25896535
4.

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Del Carmen Ordóñez M, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Gómez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2015 Mar 18;17(1):63. [Epub ahead of print]

5.

Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Corrales A, Llorca J, González-Juanatey C, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Biomed Res Int. 2015;2015:318364. doi: 10.1155/2015/318364. Epub 2015 Mar 1.

6.

Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome.

Rodríguez-Sanz A, Martínez-Sánchez P, Prefasi D, Fuentes B, Pascual-Salcedo D, Blanco-Bañares MJ, Díez-Tejedor E.

Autoimmunity. 2015 Aug;48(5):275-81. doi: 10.3109/08916934.2014.988329. Epub 2014 Dec 1.

PMID:
25434364
7.

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.

Kneepkens EL, Plasencia C, Krieckaert CL, Pascual-Salcedo D, van der Kleij D, Nurmohamed MT, López-Casla MT, Wieringa R, Rispens T, Wolbink G.

Ann Rheum Dis. 2014 Dec;73(12):2217-9. doi: 10.1136/annrheumdis-2014-205983. Epub 2014 Sep 26. No abstract available.

PMID:
25261580
8.

Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis.

Genre F, López-Mejías R, García-Bermúdez M, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2014 Sep 3;9(9):e106823. doi: 10.1371/journal.pone.0106823. eCollection 2014.

9.

Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.

Murias S, Alcobendas R, Pascual-Salcedo D, Remesal A, Peralta J, Merino R.

Rheumatology (Oxford). 2014 Nov;53(11):2124-6. doi: 10.1093/rheumatology/keu305. Epub 2014 Aug 7. No abstract available.

PMID:
25102859
10.

Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Llorca J, González-Juanatey C, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Arthritis Res Ther. 2014 Jul 10;16(4):R146. doi: 10.1186/ar4608.

11.

Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis.

López-Mejías R, Genre F, García-Bermúdez M, Ubilla B, Castañeda S, Llorca J, González-Juanatey C, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Mediators Inflamm. 2014;2014:756279. doi: 10.1155/2014/756279. Epub 2014 Mar 25.

12.

Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.

Márquez A, Ferreiro-Iglesias A, Dávila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E, Moreno-Ramos MJ, García-Portales R, Navarro F, Moreira V, Magro C, Caliz R, Ferrer MA, Alegre-Sancho JJ, Joven B, Carreira P, Balsa A, Vasilopoulos Y, Sarafidou T, Cabeza-Barrera J, Narvaez J, Raya E, Cañete JD, Fernández-Nebro A, Ordóñez Mdel C, de la Serna AR, Magallares B, Gomez-Reino JJ, González A, Martín J.

Arthritis Res Ther. 2014 Mar 11;16(2):R66. doi: 10.1186/ar4504.

13.

Single-nucleotide polymorphisms at the 9p21.3 genomic region not associated with the risk of cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

Tissue Antigens. 2013 Dec;82(6):405-9. doi: 10.1111/tan.12227. Epub 2013 Oct 15.

PMID:
24498997
14.

Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.

Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D, Moreno Ramos MJ, García-Portales R, Magro C, Alegre-Sancho JJ, Balsa A, Cabeza-Barrera J, Raya E, Martín J.

Pharmacogenet Genomics. 2014 Jan;24(1):1-5. doi: 10.1097/FPC.0000000000000013.

PMID:
24253594
15.

SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Rueda-Gotor J, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2013 Oct 21;8(10):e77695. doi: 10.1371/journal.pone.0077695. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/3fc037c1-2585-4d2b-a781-e04ab7b3bfeb.

16.

The 11q23.3 genomic region-rs964184-is associated with cardiovascular disease in patients with rheumatoid arthritis.

López-Mejías R, Genre F, García-Bermúdez M, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Rueda-Gotor J, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

Tissue Antigens. 2013 Nov;82(5):344-7. doi: 10.1111/tan.12217.

PMID:
24131021
17.

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, Peiteado D, Arribas F, Díez J, López-Casla MT, Martín-Mola E, Balsa A.

Arthritis Res Ther. 2013 Jul 26;15(4):R79. doi: 10.1186/ar4258.

18.

Association of CD247 polymorphisms with rheumatoid arthritis: a replication study and a meta-analysis.

Teruel M, McKinney C, Balsa A, Pascual-Salcedo D, Rodriguez-Rodriguez L, Ortiz AM, Gómez-Vaquero C, González-Gay MA, Smith M, Witte T, Merriman T, Lie BA, Martin J.

PLoS One. 2013 Jul 5;8(7):e68295. doi: 10.1371/journal.pone.0068295. Print 2013.

19.

Reply to: «understanding the immunogenicity concept».

Balsa A, Plasencia C, Pascual-Salcedo D.

Reumatol Clin. 2013 Jul-Aug;9(4):252-3. doi: 10.1016/j.reuma.2013.03.004. Epub 2013 Jun 6. English, Spanish. No abstract available.

20.

The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.

Plasencia Ch, Pascual-Salcedo D, Alcocer P, Bonilla MG, Villalba A, Peiteado D, Arribas F, Díez J, Lopez-Casla MT, Martín-Mola E, Balsa A.

Ann Rheum Dis. 2013 Nov;72(11):1888-90. doi: 10.1136/annrheumdis-2013-203353. Epub 2013 Jun 5. No abstract available.

PMID:
23740237
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk